Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for cerliponase alfa

  1. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.

    Highly specialised technologies guidance
    Published
    27 November 2019
    View recommendations

    Sections for HST12

  2. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]

    In development [GID-HST10061] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  3. Spotlight on innovative medicines for childhood conditions

    NICE's impact on innovative medicines for childhood conditions

  4. Past appeals and decisions

    pemetrexed 6 June 2007 TBC Lysosomal acid lipase deficiency - sebelipase alfa 25 April 2017 TA068 Macular degeneration (age-related) -...

  5. Managed access

    Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.